Genmab A/S (NASDAQ:GMAB – Get Rating) – William Blair issued their FY2022 earnings estimates for Genmab A/S in a note issued to investors on Monday, November 14th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of $1.33 for the year. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.12 per share. William Blair also issued estimates for Genmab A/S’s Q4 2022 earnings at $0.31 EPS, Q4 2022 earnings at $0.31 EPS, FY2023 earnings at $0.98 EPS, FY2024 earnings at $1.31 EPS, FY2025 earnings at $1.70 EPS and FY2026 earnings at $2.13 EPS.
A number of other brokerages have also issued reports on GMAB. Cowen raised their target price on shares of Genmab A/S to $43.00 in a research report on Tuesday. Morgan Stanley lifted their price objective on shares of Genmab A/S from $29.00 to $31.00 and gave the company an “underweight” rating in a research report on Monday, August 15th. SVB Leerink lifted their price objective on shares of Genmab A/S to $33.00 and gave the company a “market perform” rating in a research report on Thursday, November 10th. JPMorgan Chase & Co. lifted their price objective on shares of Genmab A/S from 2,900.00 to 3,450.00 and gave the company an “overweight” rating in a research report on Monday. Finally, DNB Markets lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Monday, October 17th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Genmab A/S presently has a consensus rating of “Hold” and a consensus price target of $607.12.
Genmab A/S Trading Down 0.5 %
Institutional Investors Weigh In On Genmab A/S
Institutional investors have recently made changes to their positions in the stock. Atlas Capital Advisors LLC purchased a new stake in shares of Genmab A/S during the 3rd quarter worth $29,000. Lazard Asset Management LLC raised its stake in shares of Genmab A/S by 55.9% during the 3rd quarter. Lazard Asset Management LLC now owns 1,816 shares of the company’s stock worth $56,000 after buying an additional 651 shares during the last quarter. International Biotechnology Trust PLC acquired a new position in shares of Genmab A/S during the 2nd quarter worth $57,000. Private Capital Group LLC raised its stake in shares of Genmab A/S by 14.1% during the 2nd quarter. Private Capital Group LLC now owns 2,677 shares of the company’s stock worth $87,000 after buying an additional 331 shares during the last quarter. Finally, Captrust Financial Advisors raised its stake in shares of Genmab A/S by 62.0% during the 1st quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock worth $96,000 after buying an additional 1,017 shares during the last quarter. 5.51% of the stock is currently owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.